Sandu Pharmaceuticals (524703) Q2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 25/26 earnings summary
12 Nov, 2025Executive summary
Unaudited standalone financial results for the quarter and half year ended 30th September 2025 were reviewed and approved by the Board on 12th November 2025.
Financials are prepared in accordance with Indian Accounting Standards (Ind AS) and SEBI regulations.
Financial highlights
Revenue from operations for Q2 FY26 was ₹1,762.11 lakhs, up from ₹1,669.90 lakhs in Q1 FY26 and ₹1,766.91 lakhs in Q2 FY25.
Net profit for Q2 FY26 stood at ₹52.43 lakhs, compared to ₹22.33 lakhs in Q1 FY26 and ₹50.02 lakhs in Q2 FY25.
Total comprehensive income for Q2 FY26 was ₹66.31 lakhs, compared to ₹32.66 lakhs in Q1 FY26 and ₹67.74 lakhs in Q2 FY25.
Earnings per share (basic and diluted) for Q2 FY26 was ₹0.54, up from ₹0.23 in Q1 FY26.
Outlook and guidance
Management evaluates performance based on revenue and operating income from a single segment: Ayurvedic Proprietary Medicines.
Latest events from Sandu Pharmaceuticals
- Q1 FY27 revenue reached ₹1,638.88 lakhs with net profit at ₹22.82 lakhs and EPS at ₹0.37.524703
Q1 26/27 - FY26 saw higher revenue, profit, and cash, with a Rs. 1 dividend and no large borrowings.524703Q4 25/26
- Q3 FY26 saw higher revenue and profit, with EPS at ₹1.01 and a single-segment focus.524703Q3 25/26
- Q1 FY26 saw higher revenue and profit, with AGM and dividend record date set for September.524703Q1 25/26
- Revenue and profit grew modestly; subsidiary wound up; cash reserves increased.524703Q2 24/25
- Q1 FY25 saw revenue rise to ₹1,704.54 lakhs and a recommended dividend of ₹0.80 per share.524703Q1 24/25
- Stable financial performance with steady revenue, profit, and no new borrowings or equity changes.524703Q4 23/24
- FY25 saw steady profit growth, a dividend proposal, and a shift to standalone reporting.524703Q4 24/25
- Q3 FY25 net profit more than doubled year-over-year as Sandu shifts to standalone reporting.524703Q3 24/25